Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 155

1.

Exploring emotion regulation and emotion recognition in people with presymptomatic Huntington's disease: The role of emotional awareness.

Zarotti N, Simpson J, Fletcher I, Squitieri F, Migliore S.

Neuropsychologia. 2018 Apr;112:1-9. doi: 10.1016/j.neuropsychologia.2018.02.030. Epub 2018 Mar 3.

PMID:
29510181
2.

Generation of induced pluripotent stem cell line, CSSi004-A (2962), from a patient diagnosed with Huntington's disease at the presymptomatic stage.

Bidollari E, Rotundo G, Ferrari D, Candido O, Bernardini L, Consoli F, De Luca A, Santimone I, Lamorte G, Ilari A, Squitieri F, Vescovi AL, Rosati J.

Stem Cell Res. 2018 Apr;28:145-148. doi: 10.1016/j.scr.2018.02.014. Epub 2018 Feb 21.

3.

The molecular epidemiology of Huntington disease is related to intermediate allele frequency and haplotype in the general population.

Kay C, Collins JA, Wright GEB, Baine F, Miedzybrodzka Z, Aminkeng F, Semaka AJ, McDonald C, Davidson M, Madore SJ, Gordon ES, Gerry NP, Cornejo-Olivas M, Squitieri F, Tishkoff S, Greenberg JL, Krause A, Hayden MR.

Am J Med Genet B Neuropsychiatr Genet. 2018 Apr;177(3):346-357. doi: 10.1002/ajmg.b.32618. Epub 2018 Feb 20.

PMID:
29460498
4.

Generation of induced pluripotent stem cell line, CSSi002-A (2851), from a patient with juvenile Huntington Disease.

Rosati J, Bidollari E, Rotundo G, Ferrari D, Torres B, Bernardini L, Consoli F, De Luca A, Santimone I, Lamorte G, Squitieri F, Vescovi AL.

Stem Cell Res. 2018 Mar;27:86-89. doi: 10.1016/j.scr.2018.01.011. Epub 2018 Jan 9.

5.

The contribution of gender differences in motor, behavioral and cognitive features to functional capacity, independence and quality of life in patients with Huntington's disease.

Zielonka D, Ren M, De Michele G, Roos RAC, Squitieri F, Bentivoglio AR, Marcinkowski JT, Landwehrmeyer GB.

Parkinsonism Relat Disord. 2018 Apr;49:42-47. doi: 10.1016/j.parkreldis.2018.01.006. Epub 2018 Jan 5.

PMID:
29326033
6.

Phosphorylation of huntingtin at residue T3 is decreased in Huntington's disease and modulates mutant huntingtin protein conformation.

Cariulo C, Azzollini L, Verani M, Martufi P, Boggio R, Chiki A, Deguire SM, Cherubini M, Gines S, Marsh JL, Conforti P, Cattaneo E, Santimone I, Squitieri F, Lashuel HA, Petricca L, Caricasole A.

Proc Natl Acad Sci U S A. 2017 Dec 12;114(50):E10809-E10818. doi: 10.1073/pnas.1705372114. Epub 2017 Nov 21.

7.

Cognitive Impairment in Relapsing-Remitting Multiple Sclerosis Patients with Very Mild Clinical Disability.

Migliore S, Ghazaryan A, Simonelli I, Pasqualetti P, Squitieri F, Curcio G, Landi D, Palmieri MG, Moffa F, Filippi MM, Vernieri F.

Behav Neurol. 2017;2017:7404289. doi: 10.1155/2017/7404289. Epub 2017 Aug 15.

8.

Polyglutamine tracts regulate autophagy.

Ashkenazi A, Bento CF, Ricketts T, Vicinanza M, Siddiqi F, Pavel M, Squitieri F, Hardenberg MC, Imarisio S, Menzies FM, Rubinsztein DC.

Autophagy. 2017 Sep 2;13(9):1613-1614. doi: 10.1080/15548627.2017.1336278. Epub 2017 Jul 19.

PMID:
28722507
9.

Polyglutamine expansion affects huntingtin conformation in multiple Huntington's disease models.

Daldin M, Fodale V, Cariulo C, Azzollini L, Verani M, Martufi P, Spiezia MC, Deguire SM, Cherubini M, Macdonald D, Weiss A, Bresciani A, Vonsattel JG, Petricca L, Marsh JL, Gines S, Santimone I, Marano M, Lashuel HA, Squitieri F, Caricasole A.

Sci Rep. 2017 Jul 11;7(1):5070. doi: 10.1038/s41598-017-05336-7.

10.

Executive functioning in relapsing-remitting multiple sclerosis patients without cognitive impairment: A task-switching protocol.

Migliore S, Curcio G, Couyoumdjian A, Ghazaryan A, Landi D, Moffa F, Quintiliani L, Squitieri F, Palmieri MG, Filippi MM, Vernieri F.

Mult Scler. 2017 Jul 1:1352458517719149. doi: 10.1177/1352458517719149. [Epub ahead of print]

PMID:
28675956
11.

Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study.

Hensman Moss DJ, Pardiñas AF, Langbehn D, Lo K, Leavitt BR, Roos R, Durr A, Mead S; TRACK-HD investigators; REGISTRY investigators, Holmans P, Jones L, Tabrizi SJ.

Lancet Neurol. 2017 Sep;16(9):701-711. doi: 10.1016/S1474-4422(17)30161-8. Epub 2017 Jun 20.

PMID:
28642124
12.

Resting-state connectivity and modulated somatomotor and default-mode networks in Huntington disease.

Sánchez-Castañeda C, de Pasquale F, Caravasso CF, Marano M, Maffi S, Migliore S, Sabatini U, Squitieri F.

CNS Neurosci Ther. 2017 Jun;23(6):488-497. doi: 10.1111/cns.12701. Epub 2017 May 2.

PMID:
28464463
13.

Polyglutamine tracts regulate beclin 1-dependent autophagy.

Ashkenazi A, Bento CF, Ricketts T, Vicinanza M, Siddiqi F, Pavel M, Squitieri F, Hardenberg MC, Imarisio S, Menzies FM, Rubinsztein DC.

Nature. 2017 May 4;545(7652):108-111. doi: 10.1038/nature22078. Epub 2017 Apr 26.

14.

Glucose transportation in the brain and its impairment in Huntington disease: one more shade of the energetic metabolism failure?

Morea V, Bidollari E, Colotti G, Fiorillo A, Rosati J, De Filippis L, Squitieri F, Ilari A.

Amino Acids. 2017 Jul;49(7):1147-1157. doi: 10.1007/s00726-017-2417-2. Epub 2017 Apr 10. Review.

PMID:
28396959
15.

Letter re: Huntington disease reduced penetrance alleles occur at high frequency in the general population.

Jankovic J, Squitieri F.

Neurology. 2017 Jan 17;88(3):334. doi: 10.1212/WNL.0000000000003527. No abstract available.

PMID:
28093514
16.

Early enteric neuron dysfunction in mouse and human Huntington disease.

Sciacca S, Favellato M, Madonna M, Metro D, Marano M, Squitieri F.

Parkinsonism Relat Disord. 2017 Jan;34:73-74. doi: 10.1016/j.parkreldis.2016.10.017. Epub 2016 Nov 1. No abstract available.

PMID:
27836713
17.

Clinical manifestations of intermediate allele carriers in Huntington disease.

Cubo E, Ramos-Arroyo MA, Martinez-Horta S, Martínez-Descalls A, Calvo S, Gil-Polo C; European HD Network.

Neurology. 2016 Aug 9;87(6):571-8. doi: 10.1212/WNL.0000000000002944. Epub 2016 Jul 8.

PMID:
27402890
18.

Major Superficial White Matter Abnormalities in Huntington's Disease.

Phillips OR, Joshi SH, Squitieri F, Sanchez-Castaneda C, Narr K, Shattuck DW, Caltagirone C, Sabatini U, Di Paola M.

Front Neurosci. 2016 May 23;10:197. doi: 10.3389/fnins.2016.00197. eCollection 2016.

19.

Terapeutic Potential of Microencapsulated Sertoli Cells in Huntington Disease.

Luca G, Bellezza I, Arato I, Di Pardo A, Mancuso F, Calvitti M, Falabella G, Bartoli S, Maglione V, Amico E, Favellato M, Basta G, Bodo M, Minelli A, Calafiore R, Frati L, Squitieri F.

CNS Neurosci Ther. 2016 Aug;22(8):686-90. doi: 10.1111/cns.12569. Epub 2016 May 26.

PMID:
27225886
20.

Profile of pridopidine and its potential in the treatment of Huntington disease: the evidence to date.

Squitieri F, de Yebenes JG.

Drug Des Devel Ther. 2015 Oct 28;9:5827-33. doi: 10.2147/DDDT.S65738. eCollection 2015.

Supplemental Content

Loading ...
Support Center